KALA

KALA BIO, Inc.

$0.17

-3.55%
SectorHealthcareIndustryBiotechnologyCountryUnited States

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Source: Yahoo Finance
Q-Score13/ 100
Market Cap$3.3M
P/E—
Dividend Yield0.00%
52-Week Range—
Next Earnings—
Analysts—
Beta1.34
AI summary

Price & performance

1M-65.2%
3M-74.0%
YTD-99.4%
1Y-99.6%
52-week range—
Beta1.34
Full chart and returns against a benchmark

Q-Score

13/ 100

Quality against peers; 50 is the peer median.

Growth14
Risk29
Performance11
Valuation22
Profitability23
Leverage49
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue—
Net income-$27M
Net margin—
Historical fundamentals

Red flags in filings

4active red flags
Material weakness in controlsApr 15, 2026
Late filing noticeAug 14, 2026
Auditor changeDec 29, 2025
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

KALAIndustryP/E—89.69P/S—11.88EV/EBITDA—67.10P/B0.376.22PEG—4.02
Dividend yield0.00%
Every valuation metric